MenaQ7 (Vitamin K2 MK-7, Natto-Derived)

MenaQ7 is a patented form of vitamin K2 as menaquinone-7 (MK-7) derived from natto fermentation. It activates osteocalcin and matrix Gla protein to direct calcium into bones while preventing arterial calcification.

Origin & History

MenaQ7 is a patented form of Vitamin K2, specifically MK-7, derived from natto, a traditional Japanese fermented soybean product.

Historical & Cultural Context

Vitamin K2 has been consumed in the form of natto in Japan for centuries, valued for its health benefits, particularly for bones and cardiovascular health.

Health Benefits

- Supports bone health by enhancing calcium absorption, reducing the risk of fractures by 25%. This is crucial for maintaining strong, healthy bones. - Promotes cardiovascular health by preventing arterial calcification, which can reduce the risk of heart disease. This supports a healthy circulatory system. - Enhances joint health by reducing inflammation, which can alleviate symptoms of arthritis and improve mobility. - Supports dental health by promoting strong teeth and preventing decay, which is essential for maintaining oral health. - Improves energy levels by supporting mitochondrial function, leading to increased stamina and reduced fatigue. This is important for an active lifestyle. - Acts as a powerful antioxidant, protecting cells from oxidative stress and reducing the risk of chronic diseases. This promotes overall health and longevity. - Supports immune function by modulating immune response, helping the body to fend off infections more effectively.

How It Works

MenaQ7 functions as a cofactor for gamma-glutamyl carboxylase, which carboxylates vitamin K-dependent proteins including osteocalcin and matrix Gla protein (MGP). Activated osteocalcin binds calcium in bone tissue, while carboxylated MGP prevents calcium deposition in arterial walls. This dual mechanism ensures calcium is utilized for bone mineralization rather than soft tissue calcification.

Scientific Research

Research, including clinical trials, supports MenaQ7's role in improving bone mineral density and reducing arterial stiffness.

Clinical Summary

A 3-year randomized controlled trial with 244 postmenopausal women showed 180 mcg daily MenaQ7 reduced bone loss and improved bone strength. The same study demonstrated significant reduction in arterial stiffness markers. Additional studies indicate MenaQ7 can reduce fracture risk by up to 25% and improve cardiovascular markers, though most trials are conducted in postmenopausal women with limited data in other populations.

Nutritional Profile

MenaQ7 is a highly purified, patented form of Vitamin K2 as Menaquinone-7 (MK-7), derived from fermented natto (soybeans fermented with Bacillus subtilis natto). It is not a macronutrient source and contains negligible calories, fat, protein, or carbohydrates in functional doses. Key bioactive compound: Menaquinone-7 (MK-7) — a fat-soluble vitamin belonging to the K2 subclass, typically dosed at 45–180 mcg per serving in supplemental form, with MenaQ7 standardized to ≥99% all-trans MK-7, the biologically active isomeric form. MK-7 has a long side chain (7 isoprene units) that confers exceptional bioavailability and a plasma half-life of approximately 72 hours, significantly longer than Vitamin K1 (phylloquinone, ~1–2 hours) or shorter-chain MK-4 (~6–8 hours). Bioavailability is notably fat-dependent — absorption increases substantially when taken with dietary fat due to its fat-soluble nature, utilizing chylomicron-mediated lymphatic transport. MenaQ7 activates two key carboxylation-dependent proteins: osteocalcin (bone Gla protein, BGP), which binds calcium into the bone matrix, and Matrix Gla Protein (MGP), the most potent known inhibitor of vascular calcification. At 180 mcg/day, studies show near-complete carboxylation of osteocalcin and MGP within 3 months. No significant mineral, fiber, or additional vitamin content is present at functional doses.

Preparation & Dosage

Typical dosage ranges from 90 to 200 mcg per day. Consult a healthcare provider before use.

Synergy & Pairings

Vitamin D3, Calcium, Magnesium

Safety & Interactions

MenaQ7 is generally well-tolerated with minimal side effects at recommended doses of 45-180 mcg daily. It may enhance the effects of warfarin and other anticoagulant medications, requiring medical supervision and potential dose adjustments. Unlike vitamin K1, MK-7 has a longer half-life and may have more pronounced interactions with blood thinners. Pregnant and breastfeeding women should consult healthcare providers before use due to limited safety data.